Katheryn Moreira

Articles by Katheryn Moreira

62 Integrating Dose Modifications for Effective Management of HR+, HER2– Early Breast Cancer With Abemaciclib

ByVanna Dest,Gineesha Abraham,Michelle Corso,Mattia Garutti,Katheryn Moreira,Holly Martin,Victoria J. Stefaniak,Monique Coersmeyer,Eriko Tokunaga

June 17th 2026

This review of monarchE and TRADE data demonstrates that abemaciclib dose modifications manage treatment-related adverse events without compromising efficacy in high-risk HR+, HER2− early breast cancer.

91 Real-World Survival Outcomes by Risk Features in Patients With HR+/HER2− Early Breast Cancer in the United States

ByHope S. Rugo, MD,Stephen R.D. Johnston,Javier Cortés, MD,Astra M. Liepa,Brenda R Grimes,Dan He,Katheryn Moreira,Sara M. Tolaney, MD, MPH

May 25th 2026

94 Treatment Persistence and Dose Modifications in US Patients With HR+/HER2−, Node-Positive, Early Breast Cancer Treated With Adjuvant Abemaciclib

ByHatem Soliman, MD,Susan Dent, MD,Astra M. Liepa,Victoria J. Stefaniak,Minxuan Huang,Tomoko Sugihara,Katheryn Moreira,Kathryn Hudson,Matthew P. Goetz, MD

May 24th 2026

96 Efficacy and Safety of Abemaciclib in Younger Patients With Early Breast Cancer in the monarchE Trial

ByNadia Harbeck, MD, PhD,Eleni Karapanagiotou,Fanny Le Du,Kevin Kalinsky, MD, MS,Shani Paluch-Shimon,Jasotha Sanmugarajah,Luis Costa,Einav Nili Gal-Yam,Joyce O’Shaughnessy, MD,Eriko Tokunaga,Sercan Aksoy,Rajnish Nagarkar,Brenda Grimes,Ran Jennifer Wei,Belen San Antonio,Katheryn Moreira,Hope S. Rugo, MD

May 23rd 2026

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

ByAna Sandoval,Joyce A. O’Shaughnessy,Astra M. Liepa,Brenda Grimes,Katheryn Moreira,James Roose,Catherine Keane,Sara M. Tolaney, MD, MPH

May 29th 2025

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

ByKatheryn Moreira,Kathryn Hudson,Wambui Gathirua-Mwangi,Zhanglin Lin Cui,Madeline Richey,Brenda Grimes,Jingru Wang,Astra Liepa,Erich Brechtelsbauer,Raisa Volodarsky,Hatem Soliman, MD

May 24th 2025

Katheryn Moreira

Articles by Katheryn Moreira

62 Integrating Dose Modifications for Effective Management of HR+, HER2– Early Breast Cancer With Abemaciclib

91 Real-World Survival Outcomes by Risk Features in Patients With HR+/HER2− Early Breast Cancer in the United States

94 Treatment Persistence and Dose Modifications in US Patients With HR+/HER2−, Node-Positive, Early Breast Cancer Treated With Adjuvant Abemaciclib

96 Efficacy and Safety of Abemaciclib in Younger Patients With Early Breast Cancer in the monarchE Trial

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Afami-cel in Metastatic Synovial Sarcoma

The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word

Binimetinib Tablets Receive Tentative FDA Approval in Melanoma/NSCLC

How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?

Exploring the Future of Bladder-Sparing Regimens in the MIBC Landscape